Published in Neurochem Int on June 05, 2006
The vascular contribution to Alzheimer's disease. Clin Sci (Lond) (2010) 1.21
PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med (2008) 1.17
The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int J Radiat Oncol Biol Phys (2009) 1.13
Radiation-induced cognitive impairment--from bench to bedside. Neuro Oncol (2012) 1.08
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol (2010) 1.04
Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol (2009) 1.03
Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br J Pharmacol (2011) 0.97
Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. PPAR Res (2008) 0.97
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Curr Neuropharmacol (2007) 0.94
Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist (2014) 0.92
The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. J Immunol (2008) 0.91
Pro-inflammatory gene expression and neurotoxic effects of activated microglia are attenuated by absence of CCAAT/enhancer binding protein β. J Neuroinflammation (2011) 0.90
The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab (2009) 0.90
Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease. PPAR Res (2008) 0.87
β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors. Br J Pharmacol (2012) 0.87
A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function. BMC Neurosci (2011) 0.85
The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. Radiat Res (2014) 0.84
The Neurogenic Potential of Astrocytes Is Regulated by Inflammatory Signals. Mol Neurobiol (2015) 0.84
Role of PPARs in Radiation-Induced Brain Injury. PPAR Res (2009) 0.83
MAPK induces AQP1 expression in astrocytes following injury. Glia (2010) 0.83
PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro (2013) 0.82
5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability. J Neuroinflammation (2012) 0.82
Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res (2011) 0.81
SUMOylation: Novel Neuroprotective Approach for Alzheimer's Disease? Aging Dis (2015) 0.80
Mutual induction of transcription factor PPARγ and microRNAs miR-145 and miR-329. J Neurochem (2015) 0.80
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ASN Neuro (2010) 0.78
Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs. Mol Neurobiol (2016) 0.78
Promoting return of function in multiple sclerosis: An integrated approach. Mult Scler Relat Disord (2013) 0.76
Regulation of Ketone Body Metabolism and the Role of PPARα. Int J Mol Sci (2016) 0.76
Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiol Stress (2016) 0.75
Differential peroxisome proliferator activated receptors activity in a rodent model of amyotrophic lateral sclerosis. Int J Clin Exp Med (2015) 0.75
Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery. Exp Neurol (2017) 0.75
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 4.19
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med (2009) 2.96
T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol (2007) 2.86
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity (2004) 2.24
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol (2002) 1.83
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med (2011) 1.81
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood (2004) 1.62
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta (2010) 1.50
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol (2006) 1.48
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest (2002) 1.36
miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol (2012) 1.35
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res (2005) 1.32
Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol (2005) 1.30
Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain (2011) 1.27
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J Immunol (2003) 1.21
Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem (2007) 1.19
Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.19
Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol (2005) 1.14
Monoclonal antibody therapies and neurologic disorders. Arch Neurol (2008) 1.14
Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol (2006) 1.13
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem (2012) 1.13
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol (2010) 1.13
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur J Immunol (2011) 1.06
Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One (2008) 1.05
Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol (2009) 1.03
Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol (2007) 1.03
Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol (2005) 1.02
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol (2010) 1.02
Effects of ethanol on immune response in the brain: region-specific changes in adolescent versus adult mice. Alcohol Clin Exp Res (2013) 0.98
Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol (2008) 0.98
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol (2009) 0.96
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother (2009) 0.95
miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol (2011) 0.95
Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells. Cell Immunol (2002) 0.95
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res (2012) 0.94
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol (2009) 0.93
Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J Neurosci Res (2005) 0.92
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol (2005) 0.92
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2010) 0.91
PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One (2009) 0.90
TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol (2010) 0.89
PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. PPAR Res (2008) 0.89
Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol (2004) 0.88
Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. Biochem Biophys Res Commun (2012) 0.87
Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets (2002) 0.87
PPAR-gamma: Therapeutic Potential for Multiple Sclerosis. PPAR Res (2008) 0.86
Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain (2010) 0.86
Effects of ethanol on immune response in the brain: region-specific changes in aged mice. J Neuroinflammation (2013) 0.86
Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol (2006) 0.85
Pharmacological treatment of early multiple sclerosis. Drugs (2008) 0.84
What happens when natalizumab therapy is stopped? Expert Rev Neurother (2011) 0.82
Sex steroid regulation of microglial cell activation: relevance to multiple sclerosis. Ann N Y Acad Sci (2003) 0.82
Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis. J Neuroimmunol (2011) 0.82
CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol (2006) 0.81
Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol (2006) 0.81
The potential role of B cell-targeted therapies in multiple sclerosis. Drugs (2010) 0.80
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. PPAR Res (2010) 0.80
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol (2013) 0.80
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes. Arch Neurol (2007) 0.80
Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2011) 0.79
Hormone regulation of microglial cell activation: relevance to multiple sclerosis. Brain Res Brain Res Rev (2005) 0.79
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord (2010) 0.78
Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis. J Neuroimmunol (2003) 0.78
CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE. Eur J Immunol (2007) 0.78
Therapeutic potential of small interfering RNA for central nervous system diseases. Arch Neurol (2005) 0.77
miRNAs in multiple sclerosis: regulating the regulators. J Neuroimmunol (2010) 0.77
Epstein-Barr virus and multiple sclerosis. Arch Neurol (2006) 0.76
New technologies for biomarker discovery in multiple sclerosis. J Neuroimmunol (2012) 0.76
Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain (2007) 0.76
Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis. Expert Rev Clin Immunol (2005) 0.76
Fatigue in multiple sclerosis: is the picture getting simpler or more complex? Arch Neurol (2004) 0.76
Development of spatial representation of numbers: a study of the SNARC effect in Chinese children. J Exp Child Psychol (2013) 0.76
Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res (2012) 0.76
Multiple sclerosis: Five new things. Neurol Clin Pract (2013) 0.75
Understanding the effects of FTY720 on leukocyte trafficking. Arch Neurol (2010) 0.75
Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis. J Neuroimmunol (2007) 0.75
Glatiramer acetate therapy: the plot thickens. Arch Neurol (2005) 0.75